Shamis & Gentile, P.A. is investigating claims on behalf of investors of Insperity, Inc. (“Insperity, Inc.” or the “Company”) (NSP). Impacted investors are advised to contact the firm now.
The investigation concerns whether Insperity, Inc. and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The investigation focuses on potentially misleading statements and omissions made by Insperity, Inc. regarding its financial performance and cost management during the period from April 29, 2025 through August 1, 2025.
On April 29, 2025, following the release of first quarter 2025 results that fell short of expectations and a modest revision to the Company’s outlook, Insperity, Inc. disclosed higher healthcare costs. The Company’s stock price declined approximately 12.6% to close at $68.70.
Subsequently, on August 1, 2025, Insperity, Inc. reported second quarter adjusted EPS of $0.26, significantly below the $0.41 expected by analysts, and revealed that gross profit had fallen 14% due primarily to higher-than-expected benefits costs, driven by elevated pharmacy trends and increased claim activity. Management also sharply reduced full-year 2025 adjusted EPS guidance to $1.81–$2.51.
On this news, Insperity, Inc.’s stock price fell $14.51 per share, or approximately 24.35%, to close at $45.07 on August 1, 2025.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
